InDex Pharmaceuticals discontinues cobitolimod phase III program

Contributed by: PR Newswire

Tags

Index-Pharmaceuticals

More Like This

InDex Pharmaceuticals announces that all patients needed for the cobitolimod dose selection milestone have completed Induction Study 1 of the phase III program CONCLUDE

InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea

InDex Pharmaceuticals is attending the UEGW 2023 congress

InDex Pharmaceuticals announces expected cash balance per March 31, 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis